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ABSTRACT 
Multiple Sclerosis (MS) is the most common neurological disorder in young 
adults and imposes both health and socioeconomic burdens on society. The 
cause and aetiology of MS are incompletely understood and current treatments 
are inadequate. Pathologically, prolonged chronic inflammation and 
widespread demyelination in the central nervous system leads to atrophy and 
progressive worsening of disease. This thesis combined use of in vivo animal 
models, in vitro cellular assays and in silico computational methods to 
characterise pathogenic mechanisms and translate findings from models to 
human disease. 
The animal model of MS, experimental autoimmune encephalomyelitis 
(EAE), was evaluated in light of novel findings in MS aetiology and further 
analyzed to explore differences in strain susceptibility. Susceptible rats had 
increased interleukin 7 receptor (Il7r) and Il2ra expression as well as altered 
isoform signatures in naïve lymphoid tissue, setting the stage for T cell 
differentiation towards pathogenic T helper 1 (TH1) and TH17 subtypes. 
Moreover, increased Il18r1 expression described in susceptible rats was 
explored in MS. Dysregulation of this receptor can mediate disease initiation 
through T cell differentiation as well as T cell and macrophage activation. 
IL18R1 levels were increased in peripheral immune and central nervous 
tissues in MS. Inflammatory molecules that are dysregulated in EAE likely 
represent true pathogenic mechanisms in humans. 
Multiple approaches were used to define tumour necrosis factor (TNF) 
regulation of disease severity. A region on chromosome 4 in the rat regulated 
TNF production in macrophages following innate inflammatory stimulation. 
Additional inflammatory molecules were also genetically regulated, modifying 
the cellular phenotype and severity of multiple diseases. This specific 
inflammatory control provides insight into disease pathogenesis and future 
treatment options.  
The approach of combining genetic and immunological approaches in 
both models and human samples will continue to improve disease 
understanding and provide novel therapeutics through identification of key 
regulators and general immune and non-immune pathways. 
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1 MULTIPLE SCLEROSIS 
This thesis focuses on multiple sclerosis (MS) and its animal model, 
experimental autoimmune encephalomyelitis (EAE). In vivo animal models, in 
vitro immuno-cellular assays and in silico computational approaches have been 
applied resulting in four studies aimed at delineating pathogenic mechanisms 
and translating findings for human relevance. 
 
1.1 Characteristics 
Multiple sclerosis is a chronic inflammatory disease of the central nervous 
system (CNS) that was originally described by Jean-Martin Charcot in 1868.1 It 
is the most common neurological disorder in young adults of the Western 
world. Approximately two million individuals are directly affected by this disease 
with countless others suffering economic and social burdens. Patients present 
with neurological defects, including disturbances in vision, sensation, motor 
function or autonomic problems, dependent on the location of large, multifocal, 
demyelinated plaques in the CNS.2 Extensive remyelination occurs in a subset 
of patients but with reduced density and thin myelin sheets.3 MS preferentially 
affects females and encompasses a spectrum of disease that depends on 
several pathogenic mechanisms mediated through immune cells, antibodies, 
apoptosis and degeneration.4, 5 CNS pathology includes blood-brain barrier 
(BBB) integrity breakdown and accompanying changes in both white and grey 
matter with a reduction in brain volume and axonal loss over time.6-10 
 
1.2 Clinical Course 
MS patients are defined by clinical appearance of multiple criteria, including 
oligoclonal bands in cerebrospinal fluid (CSF), lesions on magnetic resonance 
imaging (MRI) scans and bouts of neurological symptoms.11, 12 The disease 
courses encompass a multitude of neurological defects and can be classified 
into four sub-types: relapsing-remitting MS (RRMS), primary progressive MS 
(PPMS), secondary progressive MS (SPMS) and progressive relapsing MS 
(Figure 1). The majority of patients present with RRMS but often progress to a 
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SPMS sub-type, which is likely due to continued axonal loss.10 Current 
therapies target relapses but fail to slow progression in SPMS, a state without 
effective treatment possibilities.2 
 
Figure 1: Multiple sclerosis is a spectrum of 
disease courses resulting in clinical 
disability. Patients commonly experience 
relapsing-remitting MS (RRMS) and the 
majority of cases become secondary 
progressive (SPMS). However, some 
patients present with aggressive primary 
progressive (PPMS) or a progressive-
relapsing form of the disease. 
 
 
 
1.3 Autoimmunity  
Autoimmunity is defined as relating to, or caused by autoantibodies or T cells 
that attack molecules, cells, or tissues of the organism producing them. A large 
body of evidence suggests that MS is an autoimmune disease targeting the 
CNS, although some controversy surrounds this topic. MS fulfils many of the 
postulates of autoimmunity including the appearance of autoantibodies and 
autoreactive immune cells, the ability to induce an animal model with specific 
autoantigen and the possibility to transfer disease (Box 1).2, 13, 14 
Box 1: Autoimmunity postulates fulfilled by MS. 
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In further support of the autoimmune theory, the largest examination of autopsy 
brains revealed inflammation related to all demyelinating events.15 However, 
opponents state that formal proof, the transfer of disease to healthy individuals, 
has not been demonstrated. Additionally, some believe that primary defects or 
insults to the nervous system underlie MS.16 The resolution of this debate will 
help determine causative pathogenic mechanisms. 
 
1.4 Triggers 
The cause and relapse triggers of MS are currently undefined. Many 
hypotheses have been generated but causal evidence continues to elude 
investigators. Viral infections have long been associated with MS and several 
distinct viruses have been implicated in pathogenesis, including measles, 
Epstein-Barr virus (EBV), human herpes virus 6 and Torque teno virus, through 
mechanisms of molecular mimicry, inflammatory response and bystander 
activation with epitope spreading or direct demyelination.17-25 Accordingly, MS-
like disease can be induced in animals using viruses.26-29 Alternatively, 
autoreactive T cells may escape negative selection during development and 
cause disease; however, this theory would suggest that healthy individuals do 
not have these self reactive T cells, but this is not the case.30-32 Nonetheless, 
autoreactive T cells from patients have increased inflammatory capacity and 
autoreactive T cell transfer can passively induce disease in animals.33-35 
Additionally, bacterial infections may promote disease through molecular 
mimicry and degenerate T cell receptors.36 
 
1.5 Risk Factors 
Epidemiological and familial studies have 
helped frame our understanding of disease 
aetiology. MS is a complex disease with 
overlapping influences from genetics, the 
environment and epigenetic signatures 
(Figure 2). 
Figure 2:  Environmental, genetic and epigenetic factors interact and contribute to MS 
susceptibility. 
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1.5.1 Environmental Factors 
MS prevalence increases with distance from the equator, indicating a strong 
environmental influence.2 Additionally, studies of habitation highlight an 
increased risk when moving between high and low risk geographical areas 
before adolescence.37 But what factors in the temperate regions increase 
susceptibility to disease? Several explanations have been proposed including 
sun exposure, trauma, toxins, education (related to hygiene), hormones as well 
as infection type and timing.38, 39 Additionally, increases in weight and obesity 
are linked to MS susceptibility.40 Extensive studies of Vitamin D (VitD) have 
explored connections between sun exposure, genetics, diet, immunity and 
disease susceptibility; VitD seems to have protective effects against MS.41 
Finally, there is a strong link between environmental triggers such as EBV 
infection and MS induction and relapses. However, environmental exposure 
alone does not explain the distribution of MS. 
 
1.5.2 Genetic Factors 
MS is regarded as a polygenic disease in which multiple genes convey 
susceptibility. Our first understanding of genetic susceptibility to MS was 
guided by familial aggregation evidence.42, 43 Additionally, twin studies 
demonstrated increased risk in monozygotic (300-fold) compared to dizygotic 
(30-fold) twins.44 Exploration into the causative genetic component of MS 
identified the human leukocyte antigen (HLA) region.45, 46 For many years this 
was the single reproducible susceptibility locus but technological 
advancements refined our understanding; complex interactions involving Class 
I and Class II loci within the HLA are now evident. The highest risk alleles are 
the Class I HLA-A*0301 and Class II HLA-DRB1*1501 alleles.47-50 However, 
HLA-A*0201 and HLA-C*05 contribute protective effects.51, 52 Recent gene-
centred and genome-wide association scans (GWAS) have provided further 
insights into the pathogenesis of MS. Numerous candidate genes outside of 
the HLA region have been replicated  (Table 1).53-69 Additional genes continue 
to be identified and validated. However, the combined influence of the identified 
genetic factors of complex diseases explains only a small portion of the 
heritability. For example, the variants in the interleukin 7 receptor (IL7R) and 
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IL2 receptor alpha (IL2RA) genes explain only 0.2% of the variance in the risk 
of developing of MS.56 Further analyses of variants across the genome 
demonstrate only a 3% explanation of disease variance.70 This ‘missing 
heritability’ may be explained by a combination of several theories:71, 72 
  
1) Over-estimated heritable influence 
2) The locus-attributable risk is actually higher because variants are only 
proxies for true causal mutations 
3) The number of risk loci is much higher than currently identified 
4) Unidentified rare polymorphisms explain most of the genetic variance 
5) Other variants such as copy number variation contribute substantially 
6) Over-simplified models of genotype-phenotype correlation 
7) Lack of gene-gene and gene-environment (epistasis) analysis 
 
In support of some of these theories, the incorporation of more single 
nucleotide polymorphisms (SNPs) to explain genetic variance has increased 
power in new analysis, probably due to the true effect of thousands of SNPs on 
common diseases.73 Furthermore, the combination of environmental exposure 
and genetic inheritance can explain increased variance. For example, VitD 
binding to its receptor activates MS-associated HLA-DRB1*1501 gene 
transcription.74 Additionally, smoking and HLA genotypes synergistically 
regulate disease susceptibility (personal comm. T.Olsson).  
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Table 1: MS-associated genes. 
Study Type Newly Associated Genes 
Sawcer et al., 2005 Genome Linkage HLA 
Swanberg et al., 2005 Gene-Centered CIITA 
Lundmark et al., 2007 and    
Gregory et al., 2007 Gene-Centered IL7R 
Hafler et al., 2007 Genome-wide IL2R 
Rubio et al., 2008 Gene-Centered RPL5, CLEC16A 
Aulchenko et al., 2008 Gene-Centered KIF1B 
Hoppenbrouwers et al., 2008 Gene-Centered EV15 
De Jager et al., 2009 Gene-Centered CD58 
De Jager et al., 2009 Meta-Analysis CD6, IRF8, TNFRSF1A 
Hafler et al., 2009 Gene-Centered CD226 
Jagodic et al., 2009 Gene-Centered VAV1 
Jakkula et al., 2010 Gene-Centered STAT3 
Sanna et al., 2010 Gene-Centered CBLB 
IMSGC, 2010 Replication KIF21B, TMEM39A 
IMSGC, 2010 Meta-Analysis IL12A, CDK2AP1, RGS1 
 
1.5.3 Epigenetic Factors 
Epigenetics refers to the inherited changes in phenotype caused by 
mechanisms other than changes in deoxyribonucleic acid (DNA) sequence, 
including marks on nucleotides and histone proteins.75 Epigenetic modifications 
are referred to as the ‘epigenetic code’ and collectively regulate gene 
expression and may partly explain the ‘missing heritability’ in complex 
diseases. Epigenetic changes result from both extracellular and intracellular 
signalling thereby providing a link between environment, genetics and 
disease.76 Monozygotic twins with identical genomes are often discordant for 
disease, a phenomenon that can be partially explained by the epigenetic code 
controlling gene expression and disease susceptibility.77, 78 Further evidence 
comes from allelic parent-of-origin (i.e. the inheritance of alleles from the 
mother or father) effects in MS patients.79, 80 Additionally, chronic inflammation, 
as occurs in MS, mediates epigenetic changes to control disease processes. A 
specific example of DNA hypomethylation at a cytosine-guanine (CpG) island 
in the promoter region of the peptidyl argininedeiminase type II gene has been 
demonstrated in MS patients.81 
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1.5.4 Alternative Splicing 
Alternative splicing is an evolutionary mechanism to create increased 
complexity without the need to expand the genome. A single gene can encode 
messenger ribonucleic acid (mRNA) molecules that can be processed in 
multiple ways to create distinct mRNAs encoding proteins with novel functions 
(Figure 3). Alternative splicing involves the inclusion of different exons and 
occurs widely across tissues and time to control important biological 
processes.82, 83 Natural alternative splicing is dependent on cell type, genetics 
and epigenetic signatures. Dysregulated alternative splicing can result in 
disease.84, 85 Several MS-associated genes control susceptibility through 
alternative splicing; soluble versus membrane bound IL2RA and IL7R are 
examples.54, 86 However, exploration of alternative splicing and disease 
regulation has only been examined in a few select cases to date. 
 
 
 
Figure 3: Genes are encoded by coding sequences in DNA. Exons code for amino acids while 
introns are spliced out of processed messenger ribonucleic acid (mRNA). Alternative splicing 
results in different mRNA and subsequently altered proteins. 
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2 EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
The animal model for MS, namely experimental autoimmune encephalomyelitis 
(EAE), was described in the 1930s when the complications of Rabies 
vaccination were investigated in monkeys.87 Since this time EAE has been 
widely used to study pathogenic mechanisms with the assumption that there 
are conserved mechanisms leading to neuroinflammation between species. 
Most of our fundamental understanding of MS is derived from EAE studies. 
 
2.1 Models 
Many models of EAE have been developed to mimic different aspects of 
human MS. EAE can be actively induced in a number of species including 
mice, rats, guinea pigs, rabbits and monkeys using an injection of brain, myelin 
or myelin proteins together with adjuvant.88 The most commonly used adjuvant 
is Freund’s adjuvant containing mineral oil together with Mycobacterium 
tuberculosis. Injections of pertussis toxin are also necessary for several 
models. Following immunization local antigen presenting cells (APCs) take up 
emulsion and migrate to secondary lymph nodes where they activate 
autoagressive T cells. These primed T cells migrate to the CNS and cross the 
BBB using adhesion molecules.89 A cascade of immune activation follows 
reactivation of these T cells by resident APCs, including the release of tumour 
necrosis factor (TNF) and interferon-γ (IFNγ), activating resident cells and 
attracting further effector cells such as macrophages that primarily destroy 
myelin.88, 90, 91 
Both progressive and relapsing-remitting disease models have been 
generated, reflecting the variability in the human disease. For example, 
immunization with the proteolipid protein (PLP)139-151 peptide in inbred SJL 
mice induces a relapsing-remitting disease while myelin oligodendrocyte 
glycoprotein (MOG)35-55 peptide induces a chronic form of EAE in inbred 
C57BL/6 mice.92, 93 Alternatively, passive EAE can be induced through transfer 
of myelin-specific T cells.33 EAE does not naturally occur in nature but 
spontaneous models have been created using transgenic mice harbouring 
myelin-specific T and B cells.94-97 Furthermore, non-myelin autoantigens, such 
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as amyloid precursor protein and glial fibrillary acidic protein, can induce EAE, 
and degenerate MOG-specific T cell receptors may cross-react with other CNS 
antigens to initiate disease.98-100 
This thesis focuses on the widely relevant relapsing-remitting model of MOG-
induced EAE (MOG-EAE) in dark agouti (DA) inbred rats using incomplete 
Freund’s adjuvant 101 (further explained in Section 5.1). Clinical signs begin 10-
12 days after disease induction and are associated with infiltration and 
demyelination of the CNS.101, 102 DA rats demonstrate a progressive worsening 
of disease while piebald virol glaxol (PVG) inbred rats are resistant to the same 
induction protocol (Figure 4). 
  
Figure 4: DA rats are susceptible 
to EAE induction using MOG and 
develop a relapsing-remitting 
disease with bouts of increased 
demyelinaiton and motor deficit. 
 
 
 
 
 
 
2.2 Genetic Control 
Susceptibility to EAE is governed by both genetic and environmental 
influences. Both EAE and MS are polygenic diseases. Whole-genome scans in 
mice and rats have identified at least 50 quantitative trait loci (QTLs) regulating 
disease.103 These QTLs likely represent an even larger number of genes 
regulating disease because some loci with minimal effects will be missed in 
linkage studies and identified QTLs may harbour numerous genes.104-106 
Genetic susceptibility to MS and EAE appears to be very similar. The major 
histocompatibility complex (MHC), homologous to the HLA locus in humans, 
is the major genetic disease risk factor.107, 108 There is also significant overlap 
of non-MHC genes between EAE and MS.109  
The identification of genes underlying the non-MHC QTLs is a focus of our 
lab. The ultimate goal being the identification of pathogenic mechanisms for 
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better prognosis and therapeutic development. We use crosses between 
EAE-susceptible DA and EAE-resistant but MHC-identical PVG.AV1 rats to 
define QTLs across the genome regulating disease (explained in more detail 
in Section 5.2). Continued work in rats has provided insight into the regulation 
of EAE and MS including the identification of the MHC Class II transactivator 
(Ciita),53, 110 β-chemokines,104, 111 repulsive guidance molecule A (Rgma) and 
Il21r112 as well as the oncogene Vav1.65 Other genetic determinants are also 
being elucidated. 
 
2.3 Environmental and Epigenetic Influences 
EAE is a predictable model under strict environmental control that permits the 
study of the effects of modifying parameters on the induction and later disease 
stages. Several environmental influences have been identified to regulate 
disease including the use of pertussis toxin, age, seasonal variation and the 
physical structure of the inoculation emulsion.113-117  
Inheritance of disease susceptibility is complicated by parent-of-origin 
influences. Maternal and paternal transmission of alleles can be affected by 
mechanisms of genomic imprinting through epigenetic marks, mitochondrial 
inheritance and the Y chromosome, all of which have been implicated in 
EAE.102, 118, 119 Our current studies elucidating specific genetic loci in rats under 
parent-of-origin influences have demonstrated an increased power to explain 
genetic inheritance of disease susceptibility, thus contributing to the discovery 
of the ‘missing heritability’. EAE and MS are therefore similar in their 
incorporation of genetic, environmental and epigenetic influences on disease 
susceptibility. 
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3 THE IMMUNE SYSTEM 
Several lines of evidence have demonstrated that MS and EAE are immune-
mediated diseases. Firstly, the pathology of these diseases includes plaques of 
demyelination in the CNS with accompanied inflammation.15, 101 Secondly, 
autoreactive T cells and autoantibodies are commonly detected in the blood 
and CSF of patients as well as animal models.2, 13, 14, 120, 121 Thirdly, the genetic 
causes of MS and EAE are primarily components of the immune system (Table 
1). Finally, immunomodulating therapies are effective in ameliorating disease.2, 
122, 123 
 
3.1 Immune Cells 
Most immune cell subsets of both the innate and adaptive immune systems 
have been described in EAE, some with protective influences and others with 
detrimental effects. However, the reports are often contradictory and new 
theories have emerged in the past decade to further explain the complexities of 
disease. This section will concentrate on the balance of cell types, plasticity in 
the immune system and the multiple roles each cell type can perform, with a 
focus on T cells and macrophages. 
EAE and MS are described as T cell-mediated diseases because adoptive 
transfer of T cells can induce disease and T cell infiltrates are evident in EAE 
and MS lesions.33,124-127 CD8+ cytotoxic T lymphocytes (CTLs) can directly kill 
myelinating oligodendrocytes and neurons, causing disease, and are the 
predominant T cell infiltrate in MS lesions.128,129 However, CD4+ T helper (TH) 
cells are the major T cells studied in EAE. Accordingly, HLA Class I and II 
genes are implicated in MS, while MHC Class II genes are critical for EAE.47-
52,108 
The CD4+ TH lineage was a dichotomy between TH1 and TH2 commitment until 
recently when the discovery of IL23 revolutionized our understanding of the 
complexity of T cell subsets.130 IL23 shares a common p40 subunit with the 
TH1-driving IL12 cytokine but has a distinct p19 subunit.131 IL23 is critical in 
EAE because it drives induction of IL17-producing pathogenic TH17 cells.132-134 
Although both TH1 and TH17 cells can induce disease, the combination and 
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relative quantities of TH1 and TH17 cells controls the distribution of CNS 
infiltration and disease regulation.135, 136 Thus the idea of shifting the balance 
away from TH1 and IFNγ towards a TH2 response is no longer a simple option. 
Additionally, new TH phenotypes and lineages have been described, including 
IL9/IL10 producing T cells (TH9), follicular helper T cells (TFH) and regulatory T 
cells (TREGS), each phenotype being determined by stimulatory and 
costimulatory molecules on APCs, such as dendritic cells and B cells, as well 
as the local cytokine milieu (Figure 5).137-142 The specific transcription factors, 
effector molecules and cellular functions of specific TH cell subtypes are being 
investigated in normal and disease states.  
 
Figure 5: Naïve CD4+ T helper (TH0) cells can become an array of effector cells depending on 
the local cytokine environment. Each lineage is dependent on major transcription factors and 
results in a distinct pattern of cytokine production. The cell types have specialized functions 
including immunoregulation (TREGS), B cell activation (TFH) and protection (TH1, 2 and 17). 
Adapted figure.143 
 
To add to the complexity, the lineage choices are not definitive but instead 
demonstrate plasticity, with certain cytokines promoting more than one lineage 
(Figure 6). A unimodal program does not exist in T cell differentiation, as 
demonstrated by TH17 cells that can convert to TH1 cells in vivo and the ability 
of cells to secrete cytokines characteristic of multiple lineages.144, 145 
Additionally, TREGS are not stable without proper epigenetic control over specific 
genetic loci and may convert to pathogenic cells.146, 147 The quantity and 
effectiveness of T cell subsets ultimately manage a balance between 
immunosuppression and aggression. 
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Figure 6: CD4+ T helper (TH) cells can become 
immunosuppressive TREGS or autoreactive TH1 
and TH17 cells depending on the local cytokine 
milieu. The cytokines produced by each distinct 
lineage can inhibit other lineages while 
promoting positive feedback for its own 
commitment. Additionally, TH cells can switch 
between lineages under certain conditions. 
Adapted figure.148 
 
 
 
Intrinsic differences in T cells determine susceptibility to MS. Genetic 
differences in IL7R and IL2RA directly affect T cell function through regulation 
of T cell survival and development as well as TREG capacity.149, 150 
Additionally, autoaggressive T cells from MS patients are more reactive.34, 35 
TREGS would normally control these processes but their function is impaired in 
MS patients.150-152 Furthermore, priming of T cells expressing dual TCRs by 
pathogens in the periphery may induce disease during normal surveillance in 
the CNS.153 
Macrophages are myeloid derived cells that are present in all tissues.154 They 
protect against invading pathogens and clean up debris to permit biological 
turnover and function.155 Macrophages are recruited to sites of injury or 
immune stress and produce inflammatory mediators in response.156,157 In MS 
the effector cells in the CNS are infiltrating macrophages and activated 
microglia, which strip neurons of myelin to create plaques.156, 158 Accordingly, 
depletion of macrophages improves EAE.159 However, macrophages display a 
spectrum of phenotypes involved not only in active inflammation, but also in 
wound healing and resolution of immune reactions 160 (Figure 7). Subsets of 
macrophages can therefore perform different roles during disease and the 
introduction of immunomodulatory macrophages can ameliorate disease.161, 162 
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Figure 7: Macrophages respond to 
environmental cues creating a plastic 
spectrum of activation states 
characterized by expression of 
receptors and production of enzymes 
and cytokines. Adapted figure.160  
 
 
 
3.2 Cytokines 
Cytokines are small molecules that transfer signals between cells to elicit 
cellular changes in phenotype or migratory behaviour. Cytokines are often 
dichotomized into pro- and anti-inflammatory types, although the true plethora 
of their actions depends on the entire milieu, receptor expression and the 
intracellular signalling cascades. This thesis focuses on three cytokine 
pathways: IFNγ, IL18 and TNF. 
Interferons are classified into type I (IFNα and IFNβ) or type II (IFNγ) and 
modulate the immune system. The type I IFNs are produced by host cells in 
response to viral infection in order to elicit antiviral action.163 Conversely, IFNγ 
is primarily produced by activated TH1 cells and natural killer (NK) cells.164 IFNγ 
regulates MHC expression as well as mononuclear cell activation.165-167 
Furthermore, IFNγ regulates immunoglobulin isotype switching of B cells and 
controls T cell differentiation.168, 169 IFNγ is associated with TH1 responses and 
was originally considered as an evil cytokine in MS; however, IFNγ deficient 
mice develop more severe EAE.170 
Interleukin 18 is a member of the IL1 superfamily and promotes inflammatory 
responses of T cells, macrophages and NK cells.171, 172 IL18 was originally 
described as an IFNγ-inducing factor for NK cells and signals through the IL18 
receptor to cause nuclear factor κ-light-chain-enhancer of activated B cells 
(NFκB) translocation and activation 171, 173 (Figure 8). Alternatively, IL18 can 
be neutralized by the IL18 binding protein to limit its potential.174 Further effects 
in promoting TH1 cell differentiation and activating CD8+ T cells have been 
credited to this pleiotropic molecule.175, 176 MS patients have increased IL18 
levels compared to healthy controls indicating a biomarker and a pathogenic 
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mechanism.177-180 IL18 may play a role in EAE but it is not critical for disease 
induction.172, 181 
 
Figure 8: IL18 binds to the high-affinity IL18Rα and signals 
through the IL18Rβ. An intracellular signalling cascade 
results in activation of transcription factors. IL18BP (binding 
protein) can sequester free IL18 and control activity. Adapted 
figure.182 
 
 
 
 
Tumour necrosis factor was originally described as a tumour killing agent and a 
mediator of cachexia, a wasting disease.183, 184 After decades of intense 
research TNF is now known to regulate a range of biological processes 
including apoptosis, inflammatory activation and immune resolution as well as 
cellular differentiation and proliferation.185 TNF can play multiple roles in the 
immune system through action on different receptors, altered forms of the 
protein, selective localization and synergy with other molecules.186 TNF is a 
central immune mediator and control over its production and signalling is vital 
to biology; excessive TNF is associated with rheumatoid arthritis (RA), MS and 
septic shock while reduced TNF causes liver disease and opportunistic 
infection.187-190 TNF therapy has been extremely successful in treating arthritis 
as well as Crohn’s disease and ankylosing spondylitis.191 However, although 
TNF blockade is effective in EAE it had the opposing effect in MS, with patients 
developing elevated symptoms.192-194 Additionally, some RA patients receiving 
TNF treatment have developed MS-like symptoms.195 These findings point to 
the dual role TNF can have in disease regulation, both causing immune 
activation and resolving an inflammatory response.196, 197  
 
3.3 Receptors 
For cytokines to exert effects on target cells receptors must be expressed on 
their surfaces. IL18 signals through the IL18 receptor heterodimer, a part of the 
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Toll/IL1 receptor (TIR) superfamily consisting of an IL18-specific IL18Rα 
(encoded by the IL18R1 gene) and a common signalling subunit, IL18Rβ 
(Figure 8). The receptor is expressed on astrocytes, macrophages, NK, T and 
dendritic cells.176 Activation of the receptor induces differentiation of TH1 and 
TH17 cells and activation of NK cells.171, 172 IL18R1 was recently described to 
regulate EAE through IL18-dependent and –independent actions.172 
Invading pathogens need to be recognized and destroyed by the immune 
system. One mechanism for this defence is the activation of the innate toll-like 
receptor (TLR) family, which are pattern recognition receptors that bind to 
common microbial components to detect non-self antigens such as bacterial 
and fungal components.198 Binding of these antigens causes cross-linking of 
TLRs to induce intracellular signalling cascades.199 One member of this family, 
TLR4, binds to lipopolysaccharide (LPS) to induce immune responses and the 
release of TNF.200 TLR4 signals through the common myeloid differentiation 
primary response gene 88 (MyD88) as well as TNF receptor-associated factor 
(TRAF) pathways.199 The result is activation of sets of genes involved in 
antimicrobial responses and inflammatory induction.201 Several EAE models 
depend on TLR activation.202 
 
3.4 Therapeutics 
Successful treatments for MS to date have focused on the immune system. 
Many have been developed with the aid of EAE. However, several findings in 
animal models have not translated into human applications for MS, including 
IFNγ and anti-TNF treatments.88 The currently approved therapeutics include 
IFNβ, glatiramer acid, anti-α4β1 integrin antibody, intravenous immunoglobulin, 
mitoxantrone and corticosteroids.2 Additionally, two oral therapies, 
commercially known as Cladribine and Fingolimod, are undergoing approval 
(Box 2).203-205 These therapies target a variety of pathogenic mechanisms that 
ultimately modulate the immune system or cellular entry into the CNS. 
Additionally, treatments specifically targeting B cells and antibodies have been 
successful. The addition of autoreactive antibodies exacerbates disease.206, 207 
Accordingly, plasma exchange has been effective in some patients and clinical 
trials of Rituximab, a monoclonal anti-CD20 antibody that reduces B cell 
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numbers, gave promising results.208, 209 However, current treatments do not 
halt disease and remyelination after acute and chronic inflammation does not 
effectively revert disease progression.2 Additionally, immunosuppression can 
lead to infectious complications. Specifically relating to MS, several cases of 
progressive multifocal leukoencephalopathy were observed following Tysabri 
treatment.210-213  
 
Box 2: MS therapies and modes of action. 
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4 THESIS AIMS 
This thesis work set out to achieve the following scientific goals: 
 
 
1) To delineate pathogenic mechanisms in models of inflammation.  
 
2) To define genetic susceptibility loci regulating inflammation.  
 
3) To extrapolate findings from models to human disease using a  
translational approach. 
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5 METHODOLOGICAL CONSIDERATIONS 
This thesis comprises a variety of in vivo models, in vitro systems and in silico 
analyses. Some of the methodology is reviewed in the following section with a 
focus on advantages, disadvantages and technological advancements. 
 
5.1  Choice of Model 
To study MS we have employed an animal model of the human disease, 
namely MOG-EAE in DA and PVG rats. DA rats are susceptible and display a 
range of immunological and neurological deficits over time while PVG rats are 
relatively resistant to the same induction protocol. Typically, a relapsing-
remitting phenotype of ascending paralysis occurs in susceptible rats, although 
a spectrum of disease phenotypes can be observed.101, 214 The clinical 
symptoms (paralysis of the tail, wobbling gait, etc.) are the result of cellular 
infiltration in the CNS and subsequent demyelination of nerve axons. 
Importantly, MOG is the only protein known to induce a demyelinating 
autoantibody response in EAE.88 MOG-EAE thus mimics the human disease in 
a number of aspects, especially relating to the common relapsing-remitting 
subtype. Beyond its clinical aspects the MOG-EAE model has many similarities 
with regards to genetic regulation of disease susceptibility. Accordingly, this 
model is optimal for understanding pathogenic mechanisms and testing new 
therapeutics. Benefits over mouse models include the large animal size and 
milder induction protocol without the requirement of Mycobacterium 
Tuberculosis or pertussis toxin. It is also interesting to consider MOG-EAE as a 
model of pure inflammation; the recall system, whereby autoreactive cells are 
withdrawn from lymphoid tissue and restimulated with autoantigen, offers a 
model of autoimmunity and inflammatory response. 
Using an animal model has many advantages over human studies, especially 
with regard to MS because the CNS is difficult to sample (Box 3). CSF is 
routinely collected but it is questionable how the component cells, proteins and 
fluid accurately reflect the composition of the brain and spinal cord. 
Furthermore, it is difficult to correlate changes in demyelination or clinical 
disease activity to alterations in CSF or peripheral tissues such as blood. There 
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are currently no reliable relapse markers or indicators of time to the onset of 
the common secondary progressive phase. An additional difficulty of studying 
the human disease is the long time frame; disease develops over years and 
sampling is often not performed during active stages.  
 
Box 3: Benefits of EAE 
 
Although MOG-EAE has many 
similarities with MS, some 
differences are important to 
consider. MOG-EAE is an 
induced model; the cause of 
MS is unknown and the triggers 
only vaguely described, but 
induced disease is practical 
and predictable. Additionally, EAE is a CD4+ T helper cell-driven disease 
whereas patients have predominant CD8+ CTL infiltration in demyelinated 
plaques.33, 124, 129 IFNγ has been implicated in both EAE and MS 215, 216; 
however, treatment with IFNγ was effective in EAE but exacerbated MS.217 
Furthermore, the combination and balance of TH1 and TH17 cells may be 
critical in EAE although the effect on disease pathogenesis of MS is 
unknown.135 Additionally, EAE has a short duration, with experiments often 
finishing within 30 days, thus limiting its potential extrapolation to 
neurodegeneration, a key component of MS. Nonetheless, multiple models of 
EAE, inflammation and neurodegeneration may together encompass most of 
the variability and complexity of MS. 
 
5.2  Linkage Studies and Congenic Strains 
Susceptibility to EAE is a quantitative trait whereby multiple loci in the genome 
regulate disease. To define these disease-regulating QTLs we use crosses of 
inbred strains that differ in susceptibility to EAE, followed by unbiased linkage 
analysis. In linkage analysis, disease phenotypes are linked to genetic 
inheritance of regions of the genome through consequent generations. The 
  21 
crosses used in this study include F2 and advanced intercross line (AIL) 
(Figure 9). AIL mapping offers higher resolution of disease-regulating loci 
compared to F2 analysis but requires additional breeding.218 We identify 
different inherited alleles from the two parental strains using markers such as 
microsatellite markers, which are di- or tri-nucleotide repeats flanked by non-
repetitive and identifiable sequences. Markers that correlate with a disease 
phenotype lie close to the causative loci. The level of confidence for linkage is 
measured as a logarithm of odds (LOD) score; higher LOD scores mean that 
we are more certain that a particular genetic region regulates susceptibility.  
 
Figure 9: EAE-susceptible DA and EAE-resistant PVG rats can be crossed to produce different 
populations of offspring (F1, F2, G12 for example), which can be tested for linkage between 
phenotypes (EAE susceptibility for instance) and genetic loci. The resulting quantitative trait loci 
(QTLs) can be refined with further breeding (G12) and AIL mapping. Congenic rats, which 
harbour protective alleles at a QTL can be bred through backcrossing, are useful for functional 
experimentation. 
 
 
Once QTLs are identified an in-depth dissection of the genetic and functional 
processes must be undertaken. We have used congenic breeding to isolate 
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small regions of protective PVG alleles on susceptible DA backgrounds (Figure 
9). Thus a single genetic region controls the resulting effects on disease and 
pathogenic mechanisms. Some advantages of this approach include a short 
generation time using the speed congenic approach,219 the comparison of 
different naturally occurring alleles (instead of presence/absence as in 
knockout strategies) and the unlimited number of genetically identical rats. 
Recent successful attempts to resolve MS genes using congenics include 
VAV1, CIITA, IL21R and RGMA.53, 65, 110, 112 
An alternative approach to congenics is the use of genetically modified 
knockout and transgenic mice; the effect of a single gene on homeostasis and 
disease can be determined through systematic phenotyping. Although these 
models are outside the scope of this thesis, new methodology is being made 
available for rat geneticists that will offer alternative approaches. These 
techniques, including embryo culture, transposon-mediated mutagenesis and 
zinc-finger gene targeting, enable the generation of genetically modified 
knockout and transgenic rats.220-222 
 
5.3 mRNA and Protein Identification 
The identification and determination of effector molecules is a major obstacle in 
scientific studies. We have examined mRNA and protein levels in hopes of 
defining mechanisms regulating disease. We used two methods to define 
mRNA levels: real-time quantitative polymerase chain reaction (qPCR) and 
Affymetrix Arrays. qPCR utilizes fluorescent signals upon detection of target 
mRNA while Affymetrix chips use hybridization technology.223-225 The benefits 
of using mRNA as a surrogate marker for activation and response include the 
ease of tissue handling, reproducibility, sensitivity and mass data acquisition. 
These advantages are important when analyzing large numbers of precious 
human samples with reduced access to tissues such as the CNS in MS 
patients. However, not all mRNA is transcribed into protein, the true effector 
molecule. 
To measure protein levels we used enzyme-linked immunosorbent assays 
(ELISAs), which utilize specific antibodies to quantify target protein in 
samples.226 ELISA is a reliable, reproducible and efficient method making it 
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suitable for our rat studies. We used a commercial TNF ELISA kit to determine 
protein levels in supernatants from whole blood stimulated with LPS from 463 
genetically unique rats. This simple phenotype of TLR4 activation still required 
logistical planning such as careful handling of samples to ensure minimal 
degradation of protein and optimal stimulation time. The comparative use of 
several methods to define effector molecules will provide the greatest level of 
knowledge about the model system and pathogenesis. 
 
5.4 Technological Advancements 
Several technological advancements during the past decades have led to the 
rapid identification of candidate genes and targets that regulate disease. 
Sequencing technology has been at the forefront of change and has 
revolutionized genetic and functional studies. The human genome was first 
published in 2001 by two collaborative projects, a private venture using a 
whole-genome shot-gun methodology and a public initiative using bacterial 
artificial chromosome cloning methods.227, 228 The subsequent HapMap project 
followed in 2003 and gave insight into population structure and variation 
between individuals and ancestral groups.229 Next-generation sequencing 
continues to reduce costs and sequencing time; the sequences of several 
species’ genomes are now publically available, including the rat.230 New 
technology is also being developed with the capability to read single strands of 
DNA.231 
In addition to genotyping, advances in mRNA detection using expression array 
chips and plates have been made. We used Affymetrix Exon Arrays and 
Applied Biosystems TaqMan Low Density Arrays (TLDAs) in our studies.  The 
Exon Arrays test expression of all exons across the genome using hybridization 
technology; alternative splicing and gene-level expression can then be studied 
using statistical methods.232 The TLDAs offer an alternative approach using 
qPCR methodology but only explore expression across user-selected genes.233 
TLDAs are an intermediate level between individual target mRNA quantification 
and genome-wide levels in a quick, easy-to-use format. Both systems generate 
large data sets that highlight the need for computational and statistical 
improvement.  
  24 
The TLDA analysis is based on change of expression for each target compared 
to reference housekeeping genes.234 We used three housekeeping genes in 
our studies to reduce noise and experimental variance between samples, as 
could occur if housekeeping genes are regulated by stimulation. However, no 
standard method or statistical program has been developed for this purpose. 
The Exon Arrays were normalized using Robust Multi-Array Analysis (RMA), 
which accounts for whole-chip expression levels.235 To subsequently explore 
alternative splicing we applied several methods to reduce false-positives, 
although the strict approach likely increases false-negative results:  
1) Microarray Detection of Alternative Splicing (MiDAS; Alternative Transcript 
Analysis Methods for Exon Arrays; Affymetrix-White-Paper).  
2) Rank Product of Splice Index.236 
3) Alternative Splice Analysis of Variance model (Partek)  
4) Visual Discrimination of exon level expression (Partek) 
Future detection and statistical methods will likely reduce the complexity of this 
method making Exon Arrays an attractive alternative for mRNA determination. 
Alternatively, RNA sequencing offers a superior quantitative method but is 
currently hampered by high costs. 
 
5.5 Case-Control Cohorts 
Technical advancements and reduced pricing eventually gave rise to the 
possibility of genotyping large groups of diseased and control individuals. The 
frequencies of genetic variants, such as SNPs, between affected and 
unaffected individuals in a population can be tested in GWAS. This approach 
has been applied to a range of diseases in multicentre ventures and has 
identified hundreds of candidate genes (catalogued by the National Human 
Genome Research Institute; http://www.genome.gov/gwastudies/). GWAS is 
based on the common disease common variant hypothesis; common diseases 
are attributable to common allelic variants (>1% of the population) that combine 
to manifest a disease.237-240 The major benefits of association studies in 
humans include the ability to test genetic variants in unrelated individuals, the 
greater statistical power to detect common genetic variants that confer a 
modest risk and the fine localization of disease-causing variation.241 However, 
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there are also limitations: identified SNPs are often surrogate markers; very 
large cohorts are needed to detect variants with low odds ratios; strong effect 
but rare alleles are not included in the studies; population sub-structure and 
heterogeneity can affect results; and no adequate gene/gene or 
gene/environment interaction analysis is currently available.71, 242  
Several GWAS studies have been completed in MS research and a number of 
genes are associated with disease; however, a major portion of the disease 
heritability is still as yet unaccounted for (see Section 1.5.2). Nonetheless, this 
effort has identified genes that provide insight into pathogenic mechanisms and 
future increased case-control cohorts will increase power to detect variants with 
even lower odds ratios. Accordingly, there is currently an effort by the 
Wellcome Trust and a variety of institutions around the world, including 
Karolinska Institutet, to collect approximately 11,000 cases and 17,000 controls 
for an extensive MS GWAS. However, this initiative raises several questions 
about the analysis: how will the allele frequencies in different populations be 
accounted for?; how will different environmental influences be taken into 
consideration since MS is only partly hereditary?; and how will different 
diagnoses of patients reflect the spectrum and variability of MS?  
Some of the problems suggested above have been accounted for in Swedish 
association studies, including our research on IL18R1 in MS. Swedish 
biobanks offer a multitude of information for each individual through their 
personal identification number (personnummer). Knowledge about health and 
hospital visits (vaccinations, other diseases, etc.), economic status as well as 
regional living has already been gathered. The biobank also contains samples 
from blood and CSF for many patients and controls, permitting us to test the 
correlation between genotype and phenotypes, such as mRNA expression. 
Furthermore, MS patients are part of a registry that tracks the use of 
medications, relapse occurrence and disability progression. All this information 
can be taken into account for epidemiological and experimental studies. 
Additionally, a group of Swedish MS patients have been directly matched with 
controls having the same ancestry, residential area, sex and age as part of the 
Epidemiologic Investigation of Multiple Sclerosis (EIMS) study. Swedish 
cohorts thus offer a unique advantage for clinical studies on diseases such as 
MS. 
  26 
6 RESULTS AND DISCUSSION 
The four scientific papers included in this thesis (I - IV) are the result of several 
lines of investigation including the delineation of pathogenic mechanisms, the 
unbiased definition of disease-regulating genetic loci and the transition of 
findings from models to disease. 
 
6.1 Delineating Pathogenic Mechanisms of Inflammation 
We used EAE as a model of inflammation in the context of susceptible and 
resistant genetic background to assess MS candidate genes and known 
pathogenic mechanisms (I and II), alternative splicing (II) and the regulation of 
TNF (III) during disease. Genes regulating MS susceptibility have been 
identified in several GWAS and gene-centred association and linkage studies 
(Table 1). However, the assessment of biological relevance requires further 
functional experimentation. We tested the expression of several MS candidate 
genes in our MOG-EAE model in lymph nodes, the site of T cell activation and 
immune initiation, during early disease. Two of the most reproduced MS-
associated genes, IL7R and IL2RA, were upregulated in susceptible DA rat 
lymph nodes compared to resistant PVG rat lymph nodes (I) in accordance 
with other studies.243, 244 Furthermore, our genome-wide expression study 
reproduced these findings and also identified upregulation of Ev15 and Irf8 (II). 
However, Kif1b, Rpl5, Irf5, Cd226, Cd6 and Tnfrsf1a were all equally 
expressed in day 7 lymph nodes.  
We also examined pathogenic pathways during disease initiation. In mouse 
EAE TH1 and TH17 pathways are critical for disease but their contribution to our 
rat model system had not been specifically addressed. We determined that the 
lineage-specific effector molecules IFNγ, IL17 and IL22 were upregulated in the 
susceptible DA strain following restimulation with MOG autoantigen (I). The 
data support a model of TH1 and TH17 differentiation in the periphery followed 
by infiltration into the CNS and activation of effector responses. We also tested 
genome-wide pathway regulation and found enrichment for genes involved in 
glycosylation, apoptosis and cellular differentiation during early disease stages 
as well as T cell activation and apoptosis after restimulation (II). In concert with 
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these findings, autoreactive DA lymphocytes had a higher proliferative capacity 
(I). These results provide evidence that MOG-EAE is a representative model 
for human MS and provides tools to study contribution of these molecules and 
mechanisms to disease.  
Alternative splicing has recently been associated to disease whereby alternate 
isoforms of soluble and membrane bound interleukin receptors distinguish MS 
patients.54, 86 The involvement of alternative splicing in EAE disease 
susceptibility was examined using Affymetrix Exon Arrays and analytical 
methods. We studied genome-wide alternative splicing with the hypothesis that 
altered isoforms of mRNA and eventually proteins control disease states. We 
identified alternative splicing in genes involved in general signalling and 
transcriptional regulatory mechanisms (II). Nab1, Cpsf3l, Btbd10 and Usf1 
modulate transcription while Rasa1 and Rock1 control cell motility, proliferation 
and differentiation.245-250 Furthermore, five genes were constitutively spliced 
between the strains indicating important disease-regulating isoforms. 
A determinant of disease severity is the regulation of key central inflammatory 
mediators. This has been directly and indirectly demonstrated with therapies in 
autoimmune diseases. TNF blockade ameliorates RA, while blocking CNS 
entry with Tysabri and other approved MS therapies stops pro-inflammatory 
mediators from reaching their target, thus preventing disease.251, 252 We 
specifically examined the connection between TNF production and disease 
severity. Control of macrophage TNF production was associated with severity 
of EAE, sepsis, and pristine-induced arthritis (PIA) (III). These data 
demonstrate that central innate mechanisms are important in multiple diseases. 
However, no effect was evident in collagen-induced arthritis (CIA) indicating 
differences in models of RA, an important consideration when evaluating 
results. A combined approach with multiple models is therefore recommended. 
These results provide further insight into the regulation of inflammation; TNF 
production was part of a plethora of phenotypic changes occurring after TLR 
stimulation. The entire phenotype of the macrophage may therefore be critical 
in determining severity of disease through direct and subsequent indirect 
effects.  
In summary, the results from Papers I-III contribute substantial knowledge to 
mechanisms regulating inflammation. Candidate genes, T cell differentiation, 
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alternative splicing and central immune mediators control an inflammatory 
response. Susceptible DA rats had increased Il7r and Il2ra expression as well 
as altered isoform levels in naïve lymphoid tissue, setting the stage for T cell 
differentiation towards pathogenic TH1 and TH17 subtypes. The subsequent B 
cell activation mounted a humoral and adaptive response against CNS myelin. 
The migration of all these cell types caused inflammatory influx in the CNS 
leading to demyelination and EAE (Figure 10).  
 
Figure 10: Sequential events occur in EAE/MS to induce an immune response that is 
misdirected towards self-tissue and results in myelin destruction and disease symptoms. 
 
6.2 Defining Loci Regulating Inflammation 
We applied an unbiased approach of linkage analysis followed by congenic 
breeding and phenotyping to define a mechanism whereby a QTL regulated 
TNF production (III). Mapping a single trait, TNF production after TLR4 
stimulation with LPS, had a high probability of success because TNF is a 
central cytokine in inflammation that is critical in several diseases with 
susceptibility QTLs in our region of interest, including EAE and experimental 
models of neuritis and arthritis.193, 253-255 Additionally, our group previously 
demonstrated non-MHC genetic control of TNF production following LPS 
stimulation in an F2 cross, although the loci had not been refined.256 
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This project helped elucidate the mechanisms of TNF regulation and 
subsequent control of disease severity (Figure 11). The results give insight into 
varying patient responses to TNF blockade therapy. Macrophages destroy 
tissue through TNF-mediated mechanisms but some patients have low levels 
of TNF in inflamed joints and do not respond to TNF blockade.257-259 In the 
human disease no single genetic locus is attributed to this effect.260 However, 
using animal models may be beneficial because they circumvent genetic 
heterogeneity. Additionally, MS patients may develop worse disease and RA 
patients can gain MS pathologies following TNF therapy.192, 194 A focused 
treatment in macrophages could potentially ameliorate both diseases more 
effectively.  
 
 
 
 
Figure 11: Macrophages from 
susceptible and resistant 
strains respond differently to 
external innate stimuli. 
Susceptible macrophages 
initiate a strong inflammatory 
response causing severe 
disease. 
 
 
 
 
The identification of a locus regulating TNF is interesting; however, defining the 
causative allele is important for our understanding of both immune activation 
and dysregulation. By combining several methods we increase our capacity to 
define the causal gene and mechanism (Figure 12). Multiple pathways of 
macrophage activation led to same phenotype, which gives clues as to the 
responsible gene. We speculate that the effect is due to a transcription factor or 
chromatin modifier because of the extensive changes in genes encoding 
receptors, enzymes and cytokines. Additionally, the use of expression analysis 
can be useful to define candidates, as has been demonstrated for models of 
neuroinflammation,53 glomerulonephritis,261, 262 cancer,263 left ventrical mass,264 
and heart failure.265 Associated genotypes often control expression of their own 
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transcripts, as is the case for IL2RA and IL7R.55, 86 Alternatively, genes 
including RGMA, IL21R and VAV1 control effector molecules, such as IFNγ or 
TNF, as a mechanism for disease susceptibility.65, 112 
 
Figure 12: Multiple approaches can be used to determine causative genes and mechanisms 
regulating disease susceptibility and severity. 
 
In conclusion, multiple approaches were used to define a region and 
mechanism of TNF regulation and disease severity. However, further 
experimentation is required to elucidate the responsible gene. New technology, 
including knockout and transgenic rats or small interfering RNA, could rapidly 
progress this project. Additionally, the simple phenotype of whole blood 
stimulation with LPS could be used for sub-congenic breeding and the 
definition of a smaller genetic region regulating TNF, ultimately ‘positional 
cloning’ the gene. The benefits of more specific therapies will need to be 
evaluated, keeping in mind the dual roles of inflammatory mediators; TNF can 
initiate and potentiate responses, but it is also critical for resolution.197, 266 
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6.3 Translational Approach 
MS is difficult to study: it is complex; it develops over a very long timespan; 
disease encompasses a spectrum of symptoms and courses; tissues are 
difficult to obtain; the causes and pathogenesis are poorly characterized; and 
we lack diagnostic tools. However, a combined and translational approach 
provides a variety of tools to develop a deep insight into disease and treatment. 
We not only utilize in vitro and in vivo models but also have amassed a large 
biobank of human DNA as well as peripheral blood mononuclear cells 
(PBMCs) and CSF cells.  
A translational approach has been applied to understand the contribution of a 
cytokine receptor, IL18R1, in neuroinflammation and MS. Although IL18 has 
been studied in several populations and autoimmune diseases, little is known 
about the receptors’ influence. IL18 is upregulated in MS but is not critical for 
disease in experimental models.172, 177-180 However, IL18R1 is necessary for 
EAE through the influence of both IL18-dependent and -independent 
mechanisms.172  We first examined the levels of IL18R1 in susceptible and 
resistant rat strains; Il18r1 was upregulated in DA during disease initiation, 
indicating an important role in EAE pathogenesis (I). This dysregulation was 
then confirmed (II) and warranted further investigation of the receptor in 
patients. IL18R1 was increased in CSF cells and PBMCs compared to controls 
with other neurological disorders (OND) (IV and Figure 13). Interestingly, the 
receptor levels were also increased in clinically isolated syndrome (CIS) 
patients, most of whom will eventually develop MS,267 indicating IL18R1 as an 
early disease biomarker. However, receptor levels were not empirically 
regulated during disease.  
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Figure 13: A) IL18R1 is critical for EAE susceptibility (Adapted figure172). Both EAE-susceptible 
DA rats (B) and MS patients (C) have increased IL18R1 expression during disease. p.i.; post-
immunization. 
 
We next tested if polymorphisms within the IL18R1 gene associated with MS in 
a large case-control study but determined no evidence for association (IV). 
Furthermore, we investigated if polymorphisms in rat regulate Il18r1 levels in 
spleens although no cis-expression-QTL, or direct genotype-phenotype 
correlation at the Il18r1 gene, was determined. These results infer that other 
loci in the genome determine IL18R1 expression and EAE/MS susceptibility.  
Therapeutics relating to the IL18 pathway, including IL18 binding protein 
administration and IL1 cleavage enzyme (ICE; Caspase I) inhibitors, have been 
explored but off-target or weak therapeutic effects hamper their 
development.268, 269 However, monocloanal antibodies to IL18Rα have a strong 
effect on disease.172 Other antibody therapies are effective in MS (Tysabri and 
Rituximab for example) and other inflammatory diseases providing hope for 
anti-IL18Rα treatment.270  
We then tested if IL18R1 expression could be a biomarker for treatment 
evaluation. IL18R1 levels were determined before and after Tysabri treatment, 
which blocks lymphocyte trafficking to the CNS and ameliorates EAE/MS,251, 271 
but recorded no difference. This result may be due to the method of qPCR 
which measures expression on a per cell basis, because there are less 
infiltrating cells after treatment, although the same cell types and inflammatory 
mediators persist, especially in the periphery.272 Nonetheless, increased 
expression was defined in susceptible DA rats and CIS patients, indicating that 
IL18R1 may be a biomarker of disease initiation in EAE and MS.  
  33 
 
This project gives promise for translating MOG-EAE results to human MS; 
dysregulated inflammatory molecules in EAE likely represent true pathogenic 
mechanisms. The results also demonstrate immune activation in both the 
periphery and CNS of patients, providing a mechanism of IL18 and IL18R1 
dysregulation mediating disease initiation through T cell differentiation as well 
as macrophage and T cell activation (Figure 14). However, IL18R1 is not a 
biomarker for disease progression or treatment evaluation. It is interesting that 
the IL18R1 has been largely ignored in other inflammatory diseases with a vast 
amount of information linking IL18 to disease. 
 
Figure 14: The dysregulated IL18/IL18R pathway in MS leads to activation of macrophages 
and T cells with preferential enrichment of pathogenic TH1 and TH17 CD4+ as well as cytotoxic 
CD8+ cells. 
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7 POINTS OF PERSPECTIVE 
Inflammation and inflammatory diseases are difficult to study because of 
complex interactions of networks of molecules and factors, many of which are 
currently unknown or misunderstood. MS is a common complex disease with 
an incompletely defined aetiology; the causes, triggers and pathogenic 
mechanisms differ between patients and are not fully penetrant. Furthermore, 
the available diagnostics and treatments require refinement and continued 
development. This thesis aimed to understand the mechanisms underlying 
disease through hypothesis-driven research, unbiased screening and 
translational approaches. The four papers encompass a wide variety of 
methodologies and models that provide new insights, but the extrapolation and 
evaluation of the findings in the context of inflammation, autoimmunity and 
disease is vital to future studies.  
Evaluation and re-evaluation of models is a critical and an ongoing procedure. 
We tested the role of MS-associated genes in MOG-EAE in DA rats, an 
important model for therapeutic drug testing. We determined that several 
candidate genes, including Il7r, Il2ra, Irf8, and Ev15, were regulated at the level 
of expression during disease. Our results also demonstrated that similar 
mechanisms occur during MS and EAE, with TH1 and TH17 responses being 
the focus of our study. Our model thus represents a range of aspects of the 
human disease it mimics. Additional disease-genes and pathways that will be 
discovered in the future should also be evaluated in models of inflammation.  
EAE is a model of inflammation and MS but it is likely representative of a 
number of diseases. MS is an autoimmune disease, as are type 1 diabetes, 
Crohn’s disease, Hashimoto’s thyroiditis, lupus and RA. Taken together 
autoimmune diseases represent a major burden to society with approximately 
5% of the population being directly affected. These diseases share common 
mechanisms as reflected by common genetic susceptibility loci.53, 273-275 
Additionally, the CNS demyelination of MS is a key component of other 
conditions such as optic neuritis, progressive multifocal leukoencephalopathy 
and leukodystrophies. Insights into the pathology of MS and treatments aimed 
at blocking demyelination and promoting remyelination will likely be effective for 
a range of patients. Neurodegeneration is a large component of progressive 
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MS and shares similarities with Parkinson’s and Alzheimer’s diseases. 
However, the MOG-EAE model we use has a short timeline so it may not be 
optimal for studies of neurodegeneration. Our results demonstrated that alleles 
from susceptible and resistant strains can regulate central inflammatory 
mediators and are critical for severity in several diseases. Accordingly, 
therapeutics often have some effect in several inflammatory or autoimmune 
diseases: anti-CD20 therapy that targets B cells is effective in RA and has also 
shown promise in MS.209, 276 Furthermore, another approach could be the use 
of therapeutics to understand disease. We can study neuroinflammation, for 
instance, by applying effective therapies and scrutinizing the effects to better 
understand the underlying pathogenic mechanisms. 
We performed the first genome-wide alternative splicing analysis in EAE. A 
likely next step will be a follow-up in human MS. However, this may be difficult 
at a genome level because of a lack of statistical methods and comprehensive 
knowledge of mRNA processing in different tissues. Therefore, focus could be 
given to associated and known mechanisms; IL7R and IL2RA are associated 
with MS and regulate disease through alternative soluble and membrane-
bound isoforms.54, 86 Alternatively, rapidly-advancing sequencing technology 
could provide a new approach to define genetic, epigenetic and transcriptional 
control in patients.77, 78 Additionally, alternative splicing is a widespread 
phenomenon and likely contributes to natural and disease variation between 
individuals.82-85 Investigation across tissues and time-points in MS and other 
diseases may provide additional pathogenic insights. Furthermore, the 
mechanisms controlling alternative splicing, including polymorphisms, splicing 
complexes and promoter affinities are being elucidated and could be applied to 
disease susceptibility.277 
A translational approach has traditionally been successful in identifying new 
therapeutic targets and is deemed necessary for drug development. Several 
new MS therapeutics have recently been approved or are undergoing approval 
procedures, including Tysabri, as well as the first two oral medications 
Fingolimod and Cladribine. Additionally, the anti-CD20 antibody therapy 
Rituximab is effective against several autoimmune diseases including RA, type 
1 diabetes and MS.209, 278-280 However, first-line treatment retains ‘tried and 
true’ methods such as IFNβ injections. A continued mass effort aiming to 
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understand causes, define pathogenic mechanisms and develop treatment or 
even a cure will continue to dominate medical advances, although the 
complexity and heterogeneity of disease may make the road a difficult one. 
Combining genetic and immunological approaches will improve disease 
understanding and provide novel therapeutics through identification of key 
regulators and pathogenic pathways. 
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